LPCN
Closed
Lipocine Inc
3.19
+0.03 (+0.95%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.16
Day's Range: 3.11 - 3.22
Send
sign up or login to leave a comment!
When Written:
0.32
Lipocine Inc. is a pharmaceutical company that specializes in the development of oral drug delivery systems. The company's focus is on the development of oral testosterone replacement therapies for men with hypogonadism, a condition that results in low testosterone levels. Lipocine's lead product candidate, TLANDO, is an oral testosterone replacement therapy that has been designed to address the limitations of currently available testosterone replacement therapies. The company is headquartered in Salt Lake City, Utah and was founded in 2011. Lipocine is publicly traded on the NASDAQ stock exchange under the ticker symbol LPCN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








